Publications by authors named "Huiling Zhen"

Claim this Profile
P
Pemigatinib for Myeloid/Lymphoid Neoplasms with Rearrangement.
Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Jay L Patel, Alessandro Rambaldi, Huiling Zhen

NEJM Evid· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced machine learning models for predicting three-year mortality in Non-STEMI patients aged 75 and above.
Jing Zhang, Wuyu Xiong, Chengzhi Zhang, Cuiyuan Huang, Wenqiang Li, Huiling Zhen

BMC Geriatr· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced machine learning models for predicting one-year mortality in individuals suffering from type A aortic dissection.
Jing Zhang, Wuyu Xiong, Jiajuan Yang, Ye Sang, Huiling Zhen

J Thorac Cardiovasc Surg· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analyses of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement.
Xiaohua Gong, Ayman Akil, Boris Grinshpun, Jose Francis, Richard Khusial, Huiling Zhen

J Chemother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs, Huiling Zhen

Nature· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiobjective Optimization-Aided Decision-Making System for Large-Scale Manufacturing Planning.
Zhenkun Wang, Hui-Ling Zhen, Jingda Deng, Qingfu Zhang, Xijun Li

IEEE Trans Cybern· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs, Huiling Zhen

Nature· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton, Huiling Zhen

Cancer Discov· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with rearrangements.
Tanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Huiling Zhen

Future Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast Covariance Matrix Adaptation for Large-Scale Black-Box Optimization.
Zhenhua Li, Qingfu Zhang, Xi Lin, Hui-Ling Zhen

IEEE Trans Cybern· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Huiling Zhen

Lancet Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus -Paclitaxel and Gemcitabine in Advanced Solid Tumors.
Gregory L Beatty, Safi Shahda, Thaddeus Beck, Nikhil Uppal, Steven J Cohen, Huiling Zhen

Oncologist· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
Giuseppe Giaccone, Rachel E Sanborn, Saiama N Waqar, Alex Martinez-Marti, Santiago Ponce, Huiling Zhen

Clin Lung Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Jean-Jacques Kiladjian, Paola Guglielmelli, Martin Griesshammer, Guray Saydam, Tamas Masszi, Huiling Zhen

Ann Hematol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Huiling Zhen

Blood· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
Ruben Mesa, Alessandro M Vannucchi, Abdulraheem Yacoub, Pierre Zachee, Mamta Garg, Huiling Zhen

Br J Haematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Ruben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Huiling Zhen

Eur J Haematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Srdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Huiling Zhen

Haematologica· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optical rogue waves associated with the negative coherent coupling in an isotropic medium.
Wen-Rong Sun, Bo Tian, Yan Jiang, Hui-Ling Zhen

Phys Rev E Stat Nonlin Soft Matter Phys· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are clusters of mental retardation correlated with clusters of developmental delay?
Huiling Zhen, Suzanne McDermott, Andrew B Lawson, Marjorie Aelion

Geospat Health· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teaching medical students about disability in family medicine.
Catherine Leigh Graham, Rachel S Brown, Huiling Zhen, Suzanne McDermott

Fam Med· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K/AKT mediated p53 down-regulation participates in CpG DNA inhibition of spontaneous B cell apoptosis.
Yongxin Zhou, Huiling Zhen, Yunqing Mei, Yongwu Wang, Jing Feng

Cell Mol Immunol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A spatial analysis of mental retardation of unknown cause and maternal residence during pregnancy.
Huiling Zhen, Andrew B Lawson, Suzanne McDermott, Archana Pande Lamichhane, Marjorie Aelion

Geospat Health· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis